Literature DB >> 17177184

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.

Xuemei Huang1, Honglei Chen, William C Miller, Richard B Mailman, Jennifer L Woodard, Peter C Chen, Dong Xiang, Richard W Murrow, Yi-Zhe Wang, Charles Poole.   

Abstract

The apolipoprotein E (APOE) epsilon2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (> or =138 mg/dL), the OR was 2.2 (95% CI = 0.9-5.1) for participants with LDL-C of 115 to 137, 3.5 (95% CI = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% CI = 1.1-5.9) for LDL-C of < or = 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177184      PMCID: PMC1906875          DOI: 10.1002/mds.21290

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  28 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

2.  Neuroprotective effects of statins may not be related to total and low-density lipoprotein cholesterol lowering.

Authors:  Sabu J George; Abhay J Dhond; Skip M Alderson; Michael D Ezekowitz
Journal:  Am J Cardiol       Date:  2002-12-01       Impact factor: 2.778

Review 3.  Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.

Authors:  Caroline M Tanner
Journal:  Adv Neurol       Date:  2003

4.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

Review 5.  Neuroprotective properties of statins.

Authors:  Karolina Stepień; Michał Tomaszewski; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2005 Sep-Oct       Impact factor: 3.024

6.  Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study.

Authors:  L M L de Lau; M Bornebroek; J C M Witteman; A Hofman; P J Koudstaal; M M B Breteler
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

Review 7.  Apolipoprotein E: far more than a lipid transport protein.

Authors:  R W Mahley; S C Rall
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

8.  Parkinson's disease, stroke, and related epidemiology.

Authors:  Andrew Nataraj; Ali H Rajput
Journal:  Mov Disord       Date:  2005-11       Impact factor: 10.338

9.  Long-term evolution of blood lipid profiles and glycemic levels in patients after spinal cord injury.

Authors:  J Vidal; C Javierre; F J Curià; E Garrido; M-A Lizarraga; R Segura
Journal:  Spinal Cord       Date:  2003-03       Impact factor: 2.772

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  64 in total

1.  Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study.

Authors:  Louis C Tan; Kulthida Methawasin; Eng-King Tan; June H Tan; Wing-Lok Au; Jian-Min Yuan; Woon-Puay Koh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-10       Impact factor: 10.154

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Associations between cerebrovascular risk factors and parkinson disease.

Authors:  Benjamin R Kummer; Iván Diaz; Xian Wu; Ashley E Aaroe; Monica L Chen; Costantino Iadecola; Hooman Kamel; Babak B Navi
Journal:  Ann Neurol       Date:  2019-08-29       Impact factor: 10.422

6.  Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Authors:  Xuemei Huang; Alvaro Alonso; Xuguang Guo; David M Umbach; Maya L Lichtenstein; Christie M Ballantyne; Richard B Mailman; Thomas H Mosley; Honglei Chen
Journal:  Mov Disord       Date:  2015-01-14       Impact factor: 10.338

7.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

8.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2010-05-20

9.  Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent?

Authors:  Xuemei Huang; Honglei Chen; Helen Petrovitch; Richard Mailman; Webster Ross
Journal:  Mov Disord       Date:  2010-01-15       Impact factor: 10.338

10.  Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective study.

Authors:  K T Wong; J S Grove; A Grandinetti; J D Curb; M Yee; P Blanchette; G W Ross; B I Rodriguez
Journal:  Neuroepidemiology       Date:  2009-11-21       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.